Application of Rebamipide Combined with Triple Therapy in Conservative Treatment of Acute Perforation of Helicobacter Pylori-Positive Gastroduodenal Ulcer
返回论文页
|更新时间:2022-10-08
|
Application of Rebamipide Combined with Triple Therapy in Conservative Treatment of Acute Perforation of Helicobacter Pylori-Positive Gastroduodenal Ulcer
ZHANG Wenli, DING Shunbin, DONG Jiaqi, et al. Application of Rebamipide Combined with Triple Therapy in Conservative Treatment of Acute Perforation of Helicobacter Pylori-Positive Gastroduodenal Ulcer. [J]. 20(8):928-931(2020)
ZHANG Wenli, DING Shunbin, DONG Jiaqi, et al. Application of Rebamipide Combined with Triple Therapy in Conservative Treatment of Acute Perforation of Helicobacter Pylori-Positive Gastroduodenal Ulcer. [J]. 20(8):928-931(2020) DOI: 10.14009/j.issn.1672-2124.2020.08.009.
Application of Rebamipide Combined with Triple Therapy in Conservative Treatment of Acute Perforation of Helicobacter Pylori-Positive Gastroduodenal Ulcer
OBJECTIVE:To probe into the application of rebamipide combined with triple therapy in conservative treatment of acute perforation of gastroduodenal ulcer with positive Helicobacter pylori(Hp).METHODS:105 patients with acute perforation of Hp-positive gastroduodenal ulcer admitted into Deyang People’s Hospita from Oct.2015 to Dec.2019 were selected and divided into research group(55 cases) and control group(50 cases) via random number table.Both groups were given conservative treatment
the control group was given triple therapy on that basis
while the research group was treated with ribapamide based on the control group.The clinical efficacy
pepsinogen Ⅱ(PGⅡ) ] levels before and after treatment of both groups were observed
differences in incidences of adverse drug reactions during study were recorded and compared.RESULTS:The total effective rate of research group was 94.55%(52/55)
which was significantly higher than that of the control group(82.00%
41/50)
with statistically significant difference(P < 0.05).The remission time of clinical symptom
gastrointestinal decompression time and hospital stays of research group were significantly shorten than those of the control group
with statistically significant differences(P < 0.05).The Hp eradication rate of research group was 90.91%(50/55)
which was significantly higher than that of the control group(76.00%
38/50);the ulcer healing rate of research group was 87.27%(48/55)
which was significantly higher than that of the control group(68.00%
34/50)
with statistically significant differences(P<0.05).After treatment
the serum TNF-α and IL-6 levels of both groups had been significantly decreased
and those of the research group were significantly lower than the control group;after treatment
the Gas
PGⅠ and PGⅡ levels of both groups had been significantly increased
and those of the research group were significantly higher than the control group
with statistically significant differences(P<0.05).The incidences of adverse drug reactions of research group and control group were respectively 9.09%(5/55) and 12.00%(6/50)
the difference had no statistical significance(P >0.05).CONCLUSIONS:The combination of rebamipide and triple therapy can significantly relieve inflammatory reaction in conservative treatment of acute perforation of Hp-positive gastroduodenal ulcer
improve gastrointestinal function
promote ulcer healing and Hp eradication
shorten the remission time clinical symptom
gastrointestinal decompression time and hospital stays
with definite efficacy and certain clinical value.
关键词
瑞巴派特三联疗法胃十二指肠溃疡急性穿孔幽门螺杆菌
Keywords
RibapamideTriple therapyAcute perforation of gastroduodenal ulcerHelicobacter pylori